Intellikine is a private, clinical stage company based in La Jolla, California and focused on the discovery and development of innovative, orally available small molecule drugs targeting the PI3K/mTOR pathway. Mutations and dysregulation of the PI3K/mTOR pathway are strongly associated with cancer and other diseases with high unmet medical needs. Intellikine utilizes a structure-based approach to discover, build and advance one of the leading pipelines of drug candidates targeting this important pathway.